Rick Ascroft

New Capabilities

Leads US commercial launch of ILUMYA for psoriatic arthritis

The Food and Drug Administration approved ILUMYA for adults with active psoriatic arthritis on October 30, 2026. The drug, tildrakizumab, had been cleared since 2018 only for plaque psoriasis. About 2.4 million Americans have psoriatic arthritis, which causes joint pain and stiffness and can permanently damage joints.

Updated Nov 2